natgillin/translations-raw huggingface dataset:
Fycompa 10 mg film-coated tablets 10 mg – packs of 7, 28, 84 and 98
Fycompa 10 mg filmsko obložene tablete 10 mg – pakiranje po 7, 28, 84 in 98
Fycompa 12 mg film-coated tablets 12 mg – packs of 7, 28, 84 and 98
Fycompa 12 mg filmsko obložene tablete 12 mg – pakiranje po 7, 28, 84 in 98
Fycompa 4 mg film-coated tablets 4 mg – packs of 7, 28, 84 and 98
Fycompa 4 mg filmsko obložene tablete 4 mg - pakiranje po 7, 28, 84 in 98
Fycompa 6 mg film-coated tablets 6 mg – packs of 7, 28, 84 and 98
Fycompa 6 mg filmsko obložene tablete 6 mg – pakiranje po 7, 28, 84 in 98
Fycompa 8 mg film-coated tablets 8 mg – packs of 7, 28, 84 and 98
Fycompa 8 mg filmsko obložene tablete 8 mg – pakiranje po 7, 28, 84 in 98
Fycompa contains lactose
Zdravilo Fycompa vsebuje laktozo
Fycompa is available in packs of: 2 mg tablet – pack of 7, 28 and 98
Zdravilo Fycompa je na voljo v pakiranjih po: 2 mg tableta – pakiranje s 7, 28 in 98 tabletami
Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.
Zdravilo Fycompa je indicirano za dopolnilno zdravljenje parcialnih napadov s sekundarno generalizacijo ali brez nje pri odraslih bolnikih in mladostnikih z epilepsijo od starosti 12 let naprej.
Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy (see section 5.1).
Zdravilo Fycompa je indicirano za dopolnilno zdravljenje primarnih generaliziranih napadov s tonično- kloničnimi krči pri odraslih bolnikih in mladostnikih od starosti 12 let naprej z idiopatsko generalizirano epilepsijo (glejte poglavje 5.1).
Fycompa is not considered a strong inducer or inhibitor of cytochrome P450 or UGT enzymes (see section 5.2).
Zdravilo Fycompa ni močan induktor ali zaviralec citokroma P450 ali encimov UGT (glejte poglavje 5.2).
Fycompa is not recommended during pregnancy.
Zdravila Fycompa ne uporabljajte pri nosečnicah.
Fycompa is not recommended in pregnancy.
Uporaba zdravila Fycompa med nosečnostjo ni priporočljiva.
Fycompa may make certain hormonal contraceptives such as levonorgestrel less effective.
Zdravilo Fycompa lahko povzroči manjšo učinkovitost nekaterih hormonskih kontraceptivov, npr. levonorgestrela.
Fycompa may make you aggressive, angry or violent.
Zaradi zdravila Fycompa lahko postanete agresivni, jezni ali nasilni.
Fycompa may make you feel dizzy or sleepy, particularly at the beginning of treatment.
Zaradi zdravila Fycompa ste lahko omotični ali zaspani, zlasti na začetku zdravljenja.
Fycompa may make you feel dizzy or sleepy, particularly at the beginning of treatment.
Zaradi zdravila Fycompa ste omotični ali zaspani, zlasti na začetku zdravljenja.
Fycompa may make you more likely to fall over, particularly if you are an older person; this might be due to your illness.
Zaradi zdravila Fycompa se lahko poveča možnost padca, zlasti, če ste starejša oseba; vzrok za to je lahko vaša bolezen.
Fycompa must only be used as an ‘add-on’ therapy to other anti-epileptic medicines.
Zdravilo Fycompa se lahko uporablja samo kot dodatek k drugim zdravilom proti epilepsiji.
Fycompa was compared with placebo as an addition to patients’ existing epilepsy treatment.
Zdravilo Fycompa so primerjali s placebom, pri čemer so ju dodajali bolnikovim obstoječim zdravilom proti epilepsiji.
Fòti ùt 56, Budapest H-1047, Hungary
Fóti út 56, Budapest H-1047, Madžarska
Fòti ùt 56., Budapest, 1047, Hungary
Fòti ùt 56., Budapest, 1047, Madžarska
g 48 weeks of double-blind tenofovir disoproxil fumarate followed by 144 weeks open-label.
g 48-tedensko dvojno slepo zdravljenje z dizoproksiltenofovirijevim fumaratom, ki mu sledi 144-tedensko odprto zdravljenje.
g e.g. gingival bleeding, rectal haemorrhage, gastric ulcer haemorrhage
g npr. krvavitev dlesni, rektalna krvavitev, krvavitev želodčnega ulkusa
g human fibrinogen 79 mg/g human thrombin 726 IU/g
1 g 2 g humani fibrinogen 79 mg/g humani trombin 726 i.e./g
g including hot flush, feeling hot, skin warm
g vključno z vročinskimi oblivi, občutkom vročine, toplo kožo
g n=73 placebo and n=70 Humira h Spondyloarthritis Research Consortium of Canada i n=84 placebo and Humira j n=82 placebo and n=85 Humira
g n=73 placebo in n=70 zdravilo Humira h SPARCC = Kanadski raziskovalni konzorcij za spondiloartritis (Spondyloarthritis Research Consortium of Canada) i n=84 placebo in zdravilo Humira j n=82 placebo in n=85 zdravilo Humira
g once daily
0,035/0,25 mg enkrat na dan
g P-value from the Cochran Mantel-Haenszel chi-square test, with IPI and stage of disease as stratification factors. h Include all radiological CR+CRu+PR by IRC regardless the verification by bone marrow and LDH.
g vrednost p iz Cochran Mantel-Haenszelovega hi-kvadrat testa, skupaj s stratifikacijskima dejavnikoma IPI tveganjem in stopnjo bolezni. h Vključuje vse radiološke diagnostične metode CR+CRu+PR po IRC, ne glede na preverjanje kostnega mozga in LDL.
g P-value from the Cochran Mantel-Haenszel chi-square test, with IPI and stage of disease as stratification factors. h Include all radiological CR+CRu+PR by IRC regardless the verification by bone marrow and LDH.
g Vrednost p iz Cochran Mantel-Haenszelovega hi-kvadrat testa, skupaj s stratifikacijskima dejavnikoma IPI-tveganjem in stadijem bolezni. h Vključuje vse radiološke diagnostične metode CR+CRu+PR po IRC, ne glede na preverjanje kostnega mozga in LDL.
G) In GALILEO study, both control group and Eylea 2mg patients received Eylea 2 mg on an as-needed basis every 8 weeks starting from Week 52 to Week 68; patients had mandatory visits every 8 weeks.
G ) V študiji GALILEO so bolniki v kontrolni skupini in bolniki zdravljeni z zdravilom Eylea 2 mg, od 52. do 68. tedna, prejemali zdravilo Eylea 2 mg glede na potrebe vsakih 8 tednov; bolniki so imeli obvezne preglede vsakih 8 tednov.
G) In GALILEO study, both control group and Eylea 2mg patients received Eylea 2 mg on an as-needed basis every 8 weeks starting from Week 52 to Week 68; patients had mandatory visits every 8 weeks.
G) V študiji GALILEO so bolniki v kontrolni skupini in bolniki zdravljeni z zdravilom Eylea 2 mg, od 52. do 68. tedna, prejemali zdravilo Eylea 2 mg glede na potrebe vsakih 8 tednov; bolniki so imeli obvezne preglede vsakih 8 tednov.
G-CSF (5 μg/kg, SC): days 34-43
G-CSF (5 μg/kg, s.c.): 34.-43. dan
G-CSF = granulocyte colony stimulating factor, VP-16 = etoposide, MTX = methotrexate, IV = intravenous, SC = subcutaneous, IT = intrathecal, PO = oral, IM = intramuscular, ARA-C = cytarabine, CPM = cyclophosphamide, VCR = vincristine, DEX = dexamethasone, DAUN = daunorubicin, 6-MP = 6-mercaptopurine, E.Coli L-ASP = L-asparaginase, PEG-ASP = PEG asparaginase, MESNA= 2-mercaptoethane sulfonate sodium, iii= or until MTX level is < 0.1 µM, q6h
G-CSF = rastni dejavnik za granulocite (granulocyte colony stimulating factor), VP-16 = etopozid, MTX = metotreksat, i.v. = intravensko, s.c. = subkutano, i.t. = intratekalno, i.m. = intramuskularno, ARA-C = citarabin, CPM = ciklofosfamid, VCR = vinkristin, DEX = deksametazon, DAUN = daunorubicin, 6-MP = 6-merkaptopurin, E.Coli L-ASP = L-asparaginaza, PEG-ASP = PEG asparaginaza, MESNA= natrijev 2-merkaptoetan sulfonat, iii= oziroma dokler koncentracija MTX ni
G-CSF = granulocyte colony stimulating factor, VP-16 = etoposide, MTX = methotrexate, IV = intravenous, SC = subcutaneous, IT = intrathecal, PO = oral, IM = intramuscular, ARA-C = cytarabine, CPM = cyclophosphamide, VCR = vincristine, DEX = dexamethasone, DAUN = daunorubicin, 6-MP = 6-mercaptopurine, E.Coli L-ASP = L-asparaginase, PEG-ASP = PEG asparaginase, MESNA= 2-mercaptoethane sulfonate sodium, iii= or until MTX level is < 0.1 μM, q6h
G-CSF = rastni dejavnik za granulocite (granulocyte colony stimulating factor), VP-16 = etopozid, MTX = metotreksat, i.v. = intravensko, s.c. = subkutano, i.t. = intratekalno, i.m. = intramuskularno, ARA-C = citarabin, CPM = ciklofosfamid, VCR = vinkristin, DEX = deksametazon, DAUN = daunorubicin, 6-MP = 6-merkaptopurin, E.Coli L-ASP = L- asparaginaza, PEG-ASP = PEG asparaginaza, MESNA= natrijev 2-merkaptoetan sulfonat, iii= oziroma dokler koncentracija MTX ni < 0,1 µM, Gy= Gray
G-CSF can promote growth of myeloid cells in vitro and similar effects may be seen on some non- myeloid cells in vitro.
G-CSF lahko in vitro spodbuja rast mieloičnih celic; podobne učinke so in vitro opazili tudi pri nekaterih nemieloičnih celicah.
G-CSF can promote growth of myeloid cells in vitro and similar effects may be seen on some non- myeloid cells in vitro.
Granulocitne kolonije spodbujajoči faktor (G-CSF) lahko spodbudi rast mieloičnih celic in vitro in podobne učinke je mogoče videti na nekaterih ne-mieloičnih celicah in vitro.
G-CSF is used on its own for four days before Mozobil is added.
G-CSF se uporablja samostojno štiri dni pred dodajanjem zdravila Mozobil.
G-CSF prophylaxis (n = 421) n (%)
(n = 421) n (%)
G-CSF prophylaxis (n = 421) n (%)
Disgevzija (S3/4: 0,6 %),
G-CSF was administered as secondary prophylaxis to patients who experienced complicated neutropenia (febrile neutropenia, prolonged neutropenia, or infection).
Bolnice, ki so doživele zapleteno nevtropenijo (febrilna nevtropenija, dolgotrajna nevtropenija ali okužba), so kot sekundarno profilakso dobile G- CSF.
G-CSF was administered as secondary prophylaxis to patients who experienced complicated neutropenia (febrile neutropenia, prolonged neutropenia, or infection).
Bolnice, ki so doživele zapleteno nevtropenijo (febrilna nevtropenija, dolgotrajna nevtropenija ali okužba), so kot sekundarno profilakso dobile G-CSF.
G-CSF was administered as secondary prophylaxis to patients who experienced complicated neutropenia (febrile neutropenia, prolonged neutropenia, or infection).
Bolnice, ki so doživele zapleteno nevtropenijo (febrilna nevtropenija, dolgotrajna nevtropenija ali okužba), so kot sekundarno profilakso dobile GCSF.
G-CSF was used for secondary prophylaxis in 19.3% of patients (10.7% of the cycles).
G-CSF so uporabili za sekundarno profilakso pri 19,3 % bolnikov (10,7 % krogov).
G-CSF was used for secondary prophylaxis in 19.3% of patients (10.7% of the cycles).
S primarno profilakso z G-CSF
G-CSF) or to dose reduce to maintain neutrophil counts.
G-CSF) ali pa zadostno zmanjšanje odmerka, da se ohranja potrebno število nevtrofilcev.
G-CSF) or to dose reduce to maintain neutrophil counts.
G-CSF) ali zmanjšanje do odmerka, s katerim lahko vzdržujemo ustrezno število nevtrofilcev.
G-CSF) or to dose reduce to maintain neutrophil counts.
G-CSF) bodisi zmanjšanje odmerka za ohranitev števila nevtrofilcev.
g.>5.5 kb del to 3UTR
g.>5,5 kb del v 3UTR
G12P[8]
kontrol (ZDA)
G1349D (2)
Preglednica 2.
G190A/S
G109A/S
G1P[8]
primerov in
G1P[8]
Vsi RVGE
G2 2.8 x 106 Infectious Units
G2 2,8 x 106 infektivnih enot
G2  2.8 x 106 IU1
G2  2,8 x 106 i.e.1
G2P[4]
2.559 kontrol
G3 2.2 x 106 Infectious Units
G3 2,2 x 106 infektivnih enot
G3  2.2 x 106 IU1
G3  2,2 x 106 i.e.1
G3/4 ALT increased (< 1%)
S3/4 zvišanje ALT (< 1
G3/4 ALT increased (< 1%)
S3/4 zvišanje ALT (< 1 %)
G3/4 ALT increased (< 2%)
Preiskave
G3/4 ALT increased (< 2%)
S3/4 zvišanje ALT (< 2
G3/4 ALT increased (< 2%)
S3/4 zvišanje ALT (< 2 %)
G3/4 AST increased (0.5%);
povišanje ravni ALT S
G3/4 AST increased (0.5%);
S3/4 zvišanje AST (0,5
G3/4 AST increased (0.5%);
S3/4 zvišanje AST (0,5 %),
G3/4 AST increased (0.5%); G3/4 Blood alkaline phosphatase increased (0.3%)
zvečanje AST S3/4 (0,5 %), zvečanje alkalne fosfataze v krvi S3/4 (0,3 %)
G3/4 AST increased (< 1%);
S3/4 zvišanje AST (< 1
G3/4 AST increased (< 1%);
S3/4 zvišanje AST (< 1 %),
G3/4 AST increased (< 3%);
S3/4 zvišanje AST (< 3 %),
G3/4 AST increased (< 3%);
S3/4 zvišanje AST (< 3%),
G3/4 AST increased (<1%);
zvečanje AST S3/4
G3/4 Blood alkaline phosphatase increased (0.3%)
fosfataze v krvi S 3/4
G3/4 Blood alkaline phosphatase increased (0.3%)
S3/4 zvišanje alkalne fosfataze v krvi (0,3 %)
G3/4 Blood alkaline phosphatase increased (0.3%)
S3/4 zvišanje alkalne fosfataze v krvi (< 0,3
G3/4 Blood alkaline phosphatase increased (0.3%)
S3/4 zvišanje alkalne fosfataze v krvi (< 0,3 %)
G3/4 Blood alkaline phosphatase increased (< 4%);
S3/4 zvišanje alkalne fosfataze v krvi (< 4 %),
G3/4 Blood alkaline phosphatase increased (< 4%);
S3/4 zvišanje alkalne fosfataze v krvi (< 4 %), S3/4 zvišanje AST (< 3
G3/4 Blood bilirubin
zvišanje bilirubina v krvi S3/4 (< 2 %)
G3/4 Blood bilirubin increased (2.1%); G3/4 ALT increased (1.3%)
povišanje ravni bilirubina v krvi S 3/4 (< 2,1 %), povišanje ravni ALT S 3/4 (1,3 %)
G3/4 Blood bilirubin increased (2.1%); G3/4 ALT increased (1.3%)
povišanje ravni bilirubina v krvi S3/4 (< 2,1 %), povišanje ravni ALT S3/4 (1,3 %)
G3/4 Blood bilirubin increased (2.1%); G3/4 ALT increased (1.3%)
zvečanje bilirubina v krvi S3/4 (2,1 %), zvečanje ALT S3/4 (1,3 %)
G3/4 Blood bilirubin increased (2.1%); G3/4 ALT increased (1.3%)
zvečanje bilirubina v krvi S3/4 (2,1 %), zvečanje ALT S3/4 (< 1,3 %)
G3/4 Blood bilirubin increased (< 2%)
povišanje ravni bilirubina v krvi S 3/4 (< 2 %)
G3/4 Blood bilirubin increased (< 2%)
S3/4 zvišanje bilirubin v krvi (< 2 %)
G3/4 Blood bilirubin increased (< 2%)
S3/4 zvišanje bilirubin v krvi (<2%)
G3/4 Blood bilirubin increased (< 2%)
S3/4 zvišanje bilirubina v krvi ( < 2 %)
G3/4 Blood bilirubin increased (< 2%)
S3/4 zvišanje bilirubina v krvi (< 2%)
G3/4 Blood bilirubin increased (< 2%)
zvečanje bilirubina v krvi S3/4 (< 2 %)
G3/4 Blood bilirubin increased (< 2%)
zvišanje bilirubina v krvi S3/4 (< 2 %)
G3/4 Blood bilirubin increased (< 2.5%); G3/4 Blood alkaline phosphatase increased (< 2.5%)
povišanje ravni bilirubina v krvi S 3/4 (< 2,5 %), povišanje ravni alkalne fosfataze v krvi S 3/4 (< 2,5 %)
G3/4 Blood bilirubin increased (< 2.5%); G3/4 Blood alkaline phosphatase increased (< 2.5%)
povišanje ravni bilirubina v krvi S3/4 (< 2,5 %), povišanje ravni alkalne fosfataze v krvi S3/4 (< 2,5 %)
G3/4 Blood bilirubin increased (< 2.5%); G3/4 Blood alkaline phosphatase increased (< 2.5%)
S3/4 zvišanje alkalne fosfataze v krvi (< 2,5
G3/4 Blood bilirubin increased (< 2.5%); G3/4 Blood alkaline phosphatase increased (< 2.5%)
zvečanje bilirubina v krvi S3/4 (< 2,5 %), zvečanje alkalne fosfataze v krvi S3/4 (< 2,5 %)
G3/4 Blood bilirubin increased (< 2.5%); G3/4 Blood alkaline phosphatase increased (< 2.5%)
zvečanje bilirubina v krvi S3/4 (< 2,5 %), zvečanje zvečanje alkalne fosfataze v krvi S3/4 (< 2,5 %)
G3/4 Blood bilirubin increased (< 2.5%); G3/4 Blood alkaline phosphatase increased (< 2.5%)
zvišanje bilirubina v krvi S3/4 (< 2,5 %), zvišanje alkalne fosfataze v krvi S3/4 (< 2,5 %)
G3/4 Blood bilirubin increased (< 5%);
S3/4 zvišanje bilirubina v krvi (< 5 %),
G3/4 Blood bilirubin increased (< 5%); G3/4 Blood alkaline phosphatase increased (< 4%);
Splošne težave in spremembe na mestu aplikacije
G3/4 Blood bilirubin increased (<2%)
Zvečanje bilirubina v krvi S3/4 (< 2 %)
G3/4 Blood bilirubin increased (<2.5%); G3/4 Blood alkaline phosphatase increased (<2.5%)
Zvečanje bilirubina v krvi S3/4 (< 2 %)
G328E
G328R
G361R
Q357X
G373D
L372R
G373R
L372P
G375_V376del
G373R
G4 2.0 x 106 Infectious Units
G4 2,0 x 106 infektivnih enot
G4  2.0 x 106 IU1
G4  2,0 x 106 i.e.1
G801A (putative splicing site )
G801A (domnevno mesto za cepitev)
G9P[8]
47,3;71,2
Gabapentin/efavirenz
kot pri efavirenzu.
Gadolinium is used as a ‘contrast agent’ to help obtain better images with MRI scans.
Ta se uporablja kot kontrastno sredstvo, ki zagotavlja boljše slike, izdelane z magnetnoresonančnim slikanjem.
Gadolinium is used as a ‘contrast enhancer’ to help obtain better pictures with MRI scanners.
Gadolinij se uporablja kot sredstvo za povečanje kontrasta, kar zagotavlja boljše slike, izdelane z magnetnoresonančnim slikanjem (MRI).
Gadoversetamide is used as a ‘contrast agent’ in magnetic resonance imaging.
Gadoversetamid se uporablja kot kontrastno sredstvo pri magnetnoresonančnem slikanju.
Gain of ≥15 letters in visual acuity (%)a
izboljšanje ostrine vida za ≥15 črk (%)a
Gain of ≥15 letters in visual acuity at Month 12 (%)
izboljšanje za ≥15 črk ostrine vida po 12 mesecih (%)
Gain of ≥15 letters in visual acuity at Month 6a (%)
izboljšanje za ≥15 črk ostrine vida po 6 meseciha (%)
Gain of ≥15 letters or BCVA ≥84 letters at Month 12 (%)
izboljšanje za ≥15 črk ali BCVA ≥84 črk po 12 mesecih (%)
Gain of ≥15 letters or BCVA ≥84 letters at Month 24(%)
izboljšanje za ≥15 črk ali BCVA ≥84 črk po 24 mesecih (%)
Gain of ≥15 letters or BCVA ≥84 letters at Month 36 (%)
izboljšanje za ≥15 črk ali BCVA ≥84 črk po 36 mesecih (%)
GAIN: Infliximab Experienced Patients
Bolniki, ki so že dobivali infliksimab
gained ≥ 15 % and 29.1 % gained ≥ 25% of their baseline body weight.
≥ 15 % in 29,1 % ≥ 25 % od izhodiščne telesne mase.
gained ≥ 15 % and 29.1 % gained ≥ 25% of their baseline body weight.
≥ 7 %, 55,3 % ≥ 15 % in 29,1 % ≥ 25 % od njihove osnovne telesne mase.
Gaining or losing weight
povečanje ali zmanjšanje telesne mase,
Gait abnormal
nenormalna hoja
Gait abnormal Seizures
Epileptični napadi
gait abnormal, asthenia
nenormalna drža, astenija
gait abnormal, chest pain, chest discomfort, malaise, induration
nenormalna drža, bolečina v prsnem košu, neprijeten občutek v prsnem košu, splošno slabo počutje, induracija
Gait abnormality
Motnje drže
Gait abnormality
Motnje pri hoji
Gait disturbance
motnja hoje
Gait disturbance
motnje drže
gait disturbance
motnje hoje
gait disturbance
motnje pri hoji
Gait disturbance
Nenormalen
Gait disturbance
padci8 utrujenost
gait disturbance (abnormal manner of walking)
motnje hoje (nenormalen način hoje)
gait disturbance (abnormal manner of walking)
motnje hoje (nenormalen način hoje);
Gait disturbance Chest discomfort Injection site reaction
nelagodje v prsnem košu reakcija na mestu injiciranja
Gait disturbance*
motnje hoje
Galactorrhea in
galaktoreja pri
Galactorrhea in females Gynaecomastia/breast enlargement in males
Povečanje dojk Galaktoreja pri ženskah Ginekomastija/p ovečanje dojk pri moških
Galactorrhoea
zastajanje urina6
galactorrhoea, sexual dysfunction, vaginal discharge
ginekomastija, galaktoreja, spolna disfunkcija, izcedek iz nožnice
galafold 123 mg hard capsules
galafold 123 mg trde kapsule
Galafold 123 mg hard capsules
Galafold 123 mg trde kapsule migalastat
Galafold did not affect fertility in female rats.
Pri podganjih samicah zdravilo Galafold na plodnost ni vplivalo.
Galafold exposure is decreased by approximately 40% when taken with food, therefore it should not be taken within 2 hours before and after food.
Pri jemanju s hrano se izpostavljenost zdravilu Galafold zmanjša za približno 40 %, zato se ne sme jemati 2 uri pred obrokom in po njem.
Galafold is not recommended for use in patients with Fabry disease who have estimated GFR less than 30 mL/min/1.73 m2 (see section 5.2).
Uporaba zdravila Galafold ni priporočljiva pri bolnikih s Fabryjevo boleznijo, pri katerih je ocenjena stopnja glomerulne filtracije (GFR) manjša kot 30 ml/min/1,73 m2 (glejte poglavje 5.2).
Galafold is not recommended for use in patients with severe renal insufficiency, defined as estimated GFR less than 30 mL/min/1.73m2 (see section 5.2).
Uporaba zdravila Galafold ni priporočljiva pri bolnikih s hudo ledvično insuficienco, opredeljeno z ocenjeno GFR pod 30 ml/min/1,73 m2 (glejte poglavje 5.2).
Galafold is not recommended in women of childbearing potential not using contraception.
Zdravilo Galafold ni priporočljivo pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije.
gall bladder inflammation, gallstones
vnetje žolčnika, žolčni kamni;
gall bladder inflammation, gallstones.
vnetje žolčnika, žolčni kamni;
gall bladder obstruction
zaporo žolčnika,
Gall bladder perforation (not known)
perforacija žolčnika (ni znana)
Gall Bladder Wall
tena žolčnega mehurja
gall bladder wall
tena žolčnika
Gall stones
žolčni kamni,
Gall stones have been reported in patients taking atazanavir, a component of EVOTAZ. if you have type A or B haemophilia if you have problems with your kidneys or require haemodialysis.
Pri bolnikih, ki so jemali atazanavir, sestavino zdravila EVOTAZ, so poročali o pojavu žolčnih kamnov. če imate hemofilijo tipa A ali B. če imate težave z ledvicami ali se zdravite s hemodializo.
gall stones, increased bilirubin levels in the blood, abnormal liver function test
žolčni kamni, povečane ravni bilirubina v krvi, nenormalni rezultati jetrnega delovanja
Gallbladder
Žolčnik
Gallbladder disease (see section 4.4).
Bolezen žolčnika (glejte poglavje 4.4).
gallbladder inflammation, gallbladder stones
vnetje žolčnika, žolčni kamni
gallbladder inflammation, gallbladder stones;
vnetje žolčnika, žolčni kamni;
Gallbladder pain
Bolečine v žolčniku
Gallbladder problems uncommonly happen in people taking REYATAZ.
Pri osebah, ki jemljejo zdravilo REYATAZ, se občasno lahko pojavijo težave z žolčnikom.
Gallbladder Wall
Stena žolčnega mehurja
Gallbladder Wall
tena spodnjega dela debelega črevesa
Gallbladder Wall3
tena žolčnika3
gallbladder, bladder or back pain
bolečine v žolčniku, sečnem mehurju ali hrbtu
Gallions, Wexham Springs, Framewood Road, Wexham, SL3 6PJ - United Kingdom
Gallions, Wexham Springs, Framewood Road, Wexham, SL3 6PJ - Velika Britanija
Gallions, Wexham Springs, Framewood Road, Wexham, SL3 6PJ - United Kingdom
Gallions, Wexham Springs, Framewood Road, Wexham, SL3 6PJ – Velika Britanija
Gallop rhythm present
Neznano
Gallstones
Žolčni kamni
gallstones
žolčni kamni,
gallstones
žolčni kamni;
Gallstones (cholelithiasis).
žolčni kamni (holelitiaza)
Gallstones have been reported after long-term therapy
O žolčnih kamnih so poročali po dolgotrajnem zdravljenju.
Gallstones or blockage of the bile duct
žolčni kamni ali zamašen žolčevod
Gallstones.
žolčni kamni
gallstones; or if you are taking anticoagulants (medicines used to reduce the clotting ability of the blood), your doctor will monitor your coagulation parameters and may adjust your anticoagulant dose.
žolčne kamne; ali če uporabljate antikoagulante (to so zdravila, ki zavirajo zmožnost krvi, da se strjuje): v tem primeru bo zdravnik spremljal vaše parametre strjevanja krvi in vam morda spremenil odmerek antikoagulanta.
Galsulfase is comprised of 495 amino acids after cleavage of the N-terminus.
Galsulfaza vsebuje po cepitvi na N-terminalnem delu 495 aminokislin.
Galsulfase is produced by a method known as ‘recombinant DNA technology’: it is made by a cell that has received a gene (DNA), which makes it able to produce the enzyme.
Galsulfazo proizvajajo z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri celica prejme gen (DNK), s katerim lahko tvori encim.
Galvus 50 mg tablets are round, white to light yellowish and flat, with “NVR” on one side and “FB” on the other.
Tablete Galvus 50 mg so okrogle, ploščate, bele do svetlo rumenkaste barve, z napisom “NVR” na eni strani in “FB” na drugi.
Galvus can be administered with or without a meal (see also section 5.2).
Zdravilo Galvus se lahko jemlje z obrokom ali brez njega (glejte tudi poglavje 5.2).
Galvus contains lactose
Zdravilo Galvus vsebuje laktozo
Galvus contains lactose (milk sugar).
Zdravilo Galvus vsebuje laktozo (mlečni sladkor).
Galvus should not be used during breast-feeding.
Zdravila Galvus se v obdobju dojenja ne sme uporabljati.
Gambling
hazardiranje
Gamithromycin administered intramuscularly in pigs at single dose of 6 mg/kg body weight, resulted in rapid absorption with peak plasma concentrations observed after 5 to 15 min, with a long plasma half-life (about 4 days).
Po intramuskularni aplikaciji gamitromicina pri prašičih v enkratnem odmerku 6 mg/kg telesne teže, je absorbcija učinkovine izjemno hitra, z viškom koncentracije v plazmi po 5 do 15 minutah in z dolgo biološko razpolovno dobo (približno 4 dni).
Gamithromycin administered subcutaneously into the neck of cattle at a single dose of 6 mg/kg body weight, resulted in rapid absorption with peak plasma concentrations observed after 30 to 60 min with a long plasma half-life (> 2 days).
Po subkutani aplikaciji gamitromicina v predel vratu pri govedu v enkratnem odmerku 6 mg/kg telesne teže, je absorbcija učinkovine izjemno hitra, z viškom koncentracije v plazmi po 30 do 60 minutah in z dolgo biološko razpolovno dobo (>2 dni).